ClinicalTrials.gg
Status unknownNCT03351205Updated Nov 22, 2017

The Efficacy of Estrogen Therapy Against Adhesion Reformation After Hysteroscopic Adhesiolysis

An interventional study of disposable balloon uterine stent and dried biological amnion graft in Intrauterine Adhesion, sponsored by Beijing Obstetrics and Gynecology Hospital. Status unknown at 1 site in China. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2017-11-22.

Sponsored by Beijing Obstetrics and Gynecology Hospital · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Nov 2017), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Female
01

Study summary

Asherman's syndrome is characterized by the presence of intrauterine adhesions (IUA) as well as symptoms such as amenorrhea, hypomenorrhea, pelvic pain, and infertility. The gold standard for the treatment of intrauterine adhesions is hysteroscopic intrauterine adhesions. The recurrence of intrauterine adhesions is a major challenge in clinical practice. Intrauterine balloon has been used for the prevention of intrauterine adhesions. It has been reported that dried biological amnion graft was used to prevent adhesion after the operation of intrauterine adhesions. Estrogen is also used for postoperative prevention of intrauterine adhesions. Intrauterine balloon can reduce the recurrence of adhesions after operation. Disposable balloon uterine stent,which is an innovative intrauterine balloon,is specially designed to fit into the cavity of the uterus. Does Disposable balloon uterine stent and amniotic products combine estrogen therapy improve clinical outcomes? Therefore, this study was conducted.

Read the detailed description

Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double (participant and outcomes Assessor) Primary Purpose: Prevention

02

Conditions studied

  • Intrauterine Adhesion

Browse trials for

Keywords

  • Asherman syndrome
  • hysteroscopy
  • uterine stent
  • Estrogen
  • Amnion
  • Hysteroscopic Adhesiolysis
03

In context

Gynatresia

99 studies on the registry are indexed under Gynatresia; 23 are open to participants now.

This study's planned enrollment of 100 is close to the median of 100 across 87 interventional studies indexed under Gynatresia.

Browse Gynatresia studies →

Lead sponsor

Beijing Obstetrics and Gynecology Hospital is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age 20-40 years;
  • previously diagnostic hysteroscopy confirmed adhesion score >5, according to the American Fertility Society (AFS)classification of IUA;
  • complains of menstruation disorder and reproductive dysfunction;
  • .

Exclusion criteria

Exclusion Criteria:

  • premature menopause,
  • presence of other intrauterine lesions (e.g. polyps, myoma, septa), and
  • presence of severe intercurrent illness (e.g. systemic disease, coagulative disorders, severe kidney and liver diseases),
  • adhesions limited to the lower uterine cavity or the cervical canal.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Uterine cavity barrier only

    patients, who are with IUA, treated by uterine application of disposable balloon uterine stent + amnion membrane following hysteroscopic adhesiolysis.

    Device: disposable balloon uterine stent · Procedure: dried biological amnion graft

  • Experimental
    hormone

    patients, who are with IUA, treated by uterine application of disposable balloon uterine stent+ amnion membrane+hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.

    Device: disposable balloon uterine stent · Procedure: dried biological amnion graft · Drug: estradiol valerate tablets+dydrogesterone tablets

Interventions

  • Devicedisposable balloon uterine stent

    The disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to Foley catheter.

  • Proceduredried biological amnion graft

    Uterine application of dried biological amnion graft following hysteroscopic adhesiolysis. Other Name: Human amnion membrane

    Also known as: amnion membrane

  • Drugestradiol valerate tablets+dydrogesterone tablets

    Drug pages: Estradiol · Dydrogesterone

    oral estradiol valerate tablets+dydrogesterone tablets

    Also known as: Progynova+dydrogesterone

06

What researchers measure

Primary outcomes

  1. Incidence of adhesion information

    Intrauterine adhesions under hysteroscopy

    Time frame: Within the first 3 months after surgery

Secondary outcomes

  1. Menstruation Pattern

    menstrual volume which was assessed by pictorial blood loss assessment chart

    Time frame: Within the first 3 months after surgery

  2. The change of AFS score

    he American Fertility Society ( AFS ) scoring system (1988 version). Scores of 1-4, 5-8, and 9-12 were mild, moderate, and severe adhesions, respectively.

    Time frame: Within the first 3 months after surgery

07

Study locations

1 of 1 sites recruiting
  • Beijing Obstetrics and Gynecology Hospital,Capital Medical University
    Beijing, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 22, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03351205
Lead sponsor
Beijing Obstetrics and Gynecology Hospital
Responsible party
Sponsor
First posted
Nov 22, 2017
Start date
Nov 21, 2017 (estimated)
Primary completion
Nov 21, 2018 (estimated)
Completion
Nov 22, 2018 (estimated)
Last update
Nov 22, 2017

Study contacts

Zhu Ru, MD
Contact
zhuru19790202@163.com
13966636438
Wang Sha, MD
Contact
wangsha1020@163.com
15201556908
Duan Hua, MD
study chair · Beijing Obstetrics and Gynecology Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Estradiol · Dydrogesterone

Start the discussion